Page 47 - Glucose Monitoring Devices
P. 47

44     CHAPTER 3 Clinical evaluation of SMBG systems






























                         FIGURE 3.1
                         Error griddzone Adclinically accurate, zone Bdbenign errors, zones Cdovercorrection
                         errors, zone Ddfailure to detect and treat errors, zones Ederroneous errors.

                         values might result in BG values outside of the intended therapeutic range. Zone D
                         estimates are considered “dangerous failure to detect and treat” errors: the estimated
                         BG is within the therapeutic range while the actual BG is either above or below that
                         range; treatment is needed but would be omitted. Finally, zones E values are consid-
                         ered “erroneous treatment” errors. Estimates in these zones would suggest the need
                         for a treatment exactly opposite to that needed, that is, giving insulin for a BG less
                         than 70 mg/dL or giving glucose for a BG greater than 180 mg/dL.
                            Even before the results of the Diabetes Complications and Control Trial were
                         known, patient-determined SMBG was becoming a routine management tool among
                         those persons injecting insulin to manage their disease. The commercial develop-
                         ment of self-blood glucose monitors began to grow significantly and numerous
                         descriptions of their user-friendly attributes and statistical accuracy began to appear
                         in the scientific literature. Early reports of accuracy (SMBG values vs. Reference
                         values) included correlation coefficients, linear regression equations, percent devia-
                         tion, precision indexes, and standard error of measurements, but no analyses of
                         clinical accuracy [2,3]. The application of EGA to previously published statistical
                         analyses demonstrated that clinical accuracy did not always correlate with the statis-
                         tical data. In fact, no SMBG system whose data were examined using EGA produced
                         a high percentage of clinically inaccurate or unacceptable BG readings [3]. The most
                         common errors in these early studies (less than 5%) were zone D failures to detect
                         glucose values outside the treatment range. Reporting clinical accuracy in
                         performance trials of SMBG systems using EGA became more widely used and
   42   43   44   45   46   47   48   49   50   51   52